Immunotherapy

Papers
(The TQCC of Immunotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So €˜Pure’69
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar63
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study51
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma40
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study40
CT-P13 Subcutaneous Infliximab in Gastroenterology and Rheumatology38
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma35
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia31
Real-world Study of Hepatic Artery Infusion Chemotherapy Combined With Anti-PD-1 Immunotherapy and Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma29
Chimeric Antigen Receptor Macrophage for Glioblastoma Immunotherapy: The Way Forward29
Mesenchymal Stem Cells Derived from Human Dental Follicle Modulate the Aberrant Immune Response in Atopic Dermatitis27
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data26
Immunotherapy for Gastric Cancer: A 2021 Update24
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-15823
Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey21
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review20
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression19
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas18
Postvaccination immune-mediated hepatitis: what do we really know?18
Assessing Pd-L1 Status in Mrcc Treated with First-Line Immune-Based Combinations: A Meta-Analysis16
Checkpoint Inhibitors in BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Can they Help Spare the Bladder?16
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy15
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review15
Immune Checkpoint Inhibitors Use and Effects on Prognosis of COVID-19 Infection: A Systematic Review and Meta-Analysis15
Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results14
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors14
Uveitis Associated with Cancer Immunotherapy: Long-Term Outcomes13
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer13
Anlotinib Succeeded in Rescue Therapy For Hyperprogression Induced by Immune Checkpoint Inhibitors: A Case Report12
Cancer Immunotherapy Via Stem Cell-Derived NK Cells12
Safety and Efficacy of Mutant Neoantigen-Specific T-Cell Treatment Combined Anti-Pd-1 Therapy in Stage Iv Solid Tumors12
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?12
Adherence, persistence and treatment switching in psoriasis12
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis12
4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-2712
Efficacy of mIte Allergen Immunotherapy in Allergic Rhinitis and the Immune Synergistic Effect on Cross-Allergens11
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review11
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics11
SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma11
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors11
Current Immunosuppression Strategies in Pediatric Heart Transplant10
Immune-Checkpoint Inhibitors in Renal Transplanted Patients Affected by Melanoma: A Systematic Review10
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma10
Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins10
Immune Checkpoint Inhibitors in Cholangiocarcinoma10
Deucravacitinib in Moderate-To-Severe Psoriasis10
Liquid biopsy for guiding breast cancer immunotherapy10
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?10
Infection Rates and Tolerability of Three Different Immunoglobulin Administration Modalities in Patients with Primary Immunodeficiency Diseases10
Emerging Advances in Nanomedicine for Breast Cancer Immunotherapy: Opportunities and Challenges9
Applications and Current Challenges of Chimeric Antigen Receptor T Cells in Treating High-Grade Gliomas in Adult and Pediatric Populations9
Immune-Related Gigantomastia: A Case Study9
Human Growth Hormone Supplement Promotes Human Lymphohematopoietic Cell Reconstitution in Immunodeficient Mice9
Lessons From the Diagnosis and Treatment of Severe Immune Checkpoint Inhibitor-Associated Pneumonia: A Case Report9
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature9
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer9
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management9
A Summertime Pause in Immunoglobulin Replacement Therapy: A Prospective Real-World Analysis9
Poor Response to Sintilimab Plus Chemotherapy in a Pulmonary Epithelioid Hemangioendothelioma Patient: A Case Report9
Integrase inhibitors: current protagonists in antiretroviral therapy9
Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Acute and Chronic Steroid-Refractory Gvhd Mouse Models8
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens8
Ipilimumab and Nivolumab: The ‘New Kid on the Block’ in Advanced Angiosarcoma8
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs8
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report8
Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary8
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?8
Immune Checkpoint Inhibitors in Lung Tumors with Rare Histologies and Other Thoracic Malignancies8
Effectiveness of COVID-19 Vaccines Against Omicron Variant8
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib8
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis8
Abrocitinib for the Treatment of Atopic Dermatitis8
Steroid-Dependent Polyarthritis Induced by Immune Checkpoint Inhibitor Therapy Successfully Treated with Bimekizumab7
Indirect Comparison of Pembrolizumab Monotherapy Versus Nivolumab + Ipilimumab in First-Line Metastatic Lung Cancer7
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes7
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma7
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis7
Therapeutic Intervention of Glioma with the Novel Antineoplastic Agent T11TS: The Story so Far7
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma7
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy7
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events7
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis7
Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients7
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer7
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors7
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease7
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab6
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China6
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer6
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus6
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases6
The Effect of Low-Dose Chemotherapy on the Tumor Microenvironment and its Antitumor Activity Combined with Anti-PD-1 Antibody6
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis6
Could senescent cells be the prescription for therapeutic cancer vaccines?6
Immunotherapies for prevention and treatment of type 1 diabetes6
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review6
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)6
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas6
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan6
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study6
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis6
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis6
Urothelial Carcinoma in The Era of Immune Checkpoint Inhibitors6
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis6
Pembrolizumab in an HIV-infected patient with glioblastoma6
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy6
Allogeneic CAR-T cells for cancer immunotherapy6
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review6
Therapeutic Cancer Vaccine Therapy for Acute Myeloid Leukemia6
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy6
Neoadjuvant Immunochemotherapy in the Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: A Systematic Review6
Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma6
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?6
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database6
Oncolytic Viruses in Lung Cancer Treatment: A Review Article5
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates5
Chemotherapy or Chemo-Immunotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer: A Meta-Analysis5
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents5
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy5
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review5
Amalgamation of Nanotechnology with Chicken IgY to Enrich Therapeutic and Diagnostic Applications: A Systematic Review5
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study5
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis5
Peripheral Blood Eosinophil Count is Associated with Response to Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer5
Tsunami of Immunotherapies in the Management of Esophageal Cancer5
Infrequent Liver Injury from Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma5
Treatment of Children with Primary Immunodeficiencies with a Subcutaneous Immunoglobulin 16.5% (Cutaquig ®  [Octanorm])5
ICAM2 is Related to Good Prognosis in Dendritic Cell Immunotherapy for Cancer5
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations5
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma5
Nivolumab-Induced Systemic Capillary Leak Syndrome as an Ultra Rare Life-Threatening Phenomenon of Late Toxicity and Intravenous Immunoglobulin Efficacy5
Pembrolizumab: A New Standard of Care in Metastatic Colorectal Cancer5
Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment5
Peptide–MHC Complexes: Dressing up to Manipulate T Cells Against Autoimmunity and Cancer5
Anaphylaxis to Tocilizumab in Patients with Rheumatic Disease5
An Unusual Case of Immune-Related Gastritis in One Patient Receiving Toripalimab Therapy5
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary5
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study5
Abscopal Effect and Resistance Reversion in Nivolumab-Treated Non-Small-Cell Lung Cancer Undergoing Palliative Radiotherapy: A Case Report5
A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells5
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery5
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement5
Radiation and Resolve: Unlocking the Synergistic Potential of Radioimmunotherapy in Advanced Lung Cancer Management5
Pd-1/L1 Inhibitors May Increase the Risk of Pericardial Disease in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis and Systematic Review5
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?5
Targeting the Tumor Microenvironment of Ewing Sarcoma5
0.055530071258545